<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305316</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-120</org_study_id>
    <nct_id>NCT02305316</nct_id>
  </id_info>
  <brief_title>Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone</brief_title>
  <official_title>Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-centre, open-label, randomised, two-way crossover study in 28 healthy volunteers. The
      study consisted of two consecutive single-dose treatment periods separated by a washout
      period of 14 days or more.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-centre, open-label, randomised, two-way crossover study in 28 healthy volunteers. The
      study consisted of two consecutive single-dose treatment periods separated by a washout
      period of 14 days or more. A total of twenty-eight (28) healthy volunteers received a single
      dose of 50 mg OPC, orally.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Observed Plasma Concentration</measure>
    <time_frame>before OPC dosing, and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-OPC dose.</time_frame>
    <description>Maximum observed plasma concentration of BIA 9-1067</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-t - Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration</measure>
    <time_frame>before OPC dosing, and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-OPC dose.</time_frame>
    <description>AUC0-t - Area under the plasma concentration-time curve from time 0 to the time of last quantifiable concentration of BIA 9-1067</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax - Time of Occurrence of Cmax of BIA 9-1067</measure>
    <time_frame>before OPC dosing, and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-OPC dose.</time_frame>
    <description>tmax - time of occurrence of maximum observed plasma concentration of BIA 9-1067</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf - Area Under the Plasma Concentration-time Curve From Time 0 to the Infinity</measure>
    <time_frame>before OPC dosing, and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-OPC dose.</time_frame>
    <description>AUC0-inf - Area under the plasma concentration-time curve from time 0 to the infinity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>BIA 9-1067 non-micronized - micronized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject was orally administered with 50 mg OPC non-micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC micronized</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 micronized - non-micronized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject was orally administered 50 mg OPC micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC non-micronized</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067 non-micronized</intervention_name>
    <arm_group_label>BIA 9-1067 non-micronized - micronized</arm_group_label>
    <arm_group_label>BIA 9-1067 micronized - non-micronized</arm_group_label>
    <other_name>OPC, Opicapone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067 micronized</intervention_name>
    <arm_group_label>BIA 9-1067 non-micronized - micronized</arm_group_label>
    <arm_group_label>BIA 9-1067 micronized - non-micronized</arm_group_label>
    <other_name>OPC, Opicapone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed and dated informed consent form (ICF) before any study-specific screening
             procedure was performed,

          -  Male or female subjects aged 18 to 45 years, inclusive,

          -  Body mass index (BMI) between 19 and 30 kg/m2,

          -  Healthy as determined by pre-study medical history, physical examination, vital signs,
             complete neurological examination and 12-lead electrocardiogram (ECG),

          -  Negative tests for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV)
             antibodies and anti-human immunodeficiency virus (HIV) antibodies at screening,

          -  Clinical laboratory test results clinically acceptable at screening and on D-1 of each
             treatment period,

          -  Negative screen for alcohol and drugs of abuse at screening and on D-1 of each
             treatment period,

          -  Non-smokers or ex-smokers for at least 3 months,

          -  Volunteer able to participate, and willing to give written informed consent and comply
             with the study restrictions,

        If female:

          -  Was not of childbearing potential by reason of surgery or, if of childbearing
             potential, uses an effective non-hormonal method of contraception (intrauterine device
             or intrauterine system; condom or occlusive cap [diaphragm or cervical or vault caps]
             with spermicidal foam or gel or film or cream or suppository; true abstinence; or
             vasectomized male partner, provided that he was the sole partner of that subject) for
             the entire duration of the study,

          -  Negative serum pregnancy test at screening and a negative urine pregnancy test on D-1
             of each treatment period.

        Exclusion Criteria:

          -  Any clinically relevant history or presence of respiratory, gastrointestinal, renal,
             hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric,
             musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective
             tissue diseases or disorders, or had a clinically relevant surgical history,

          -  Any clinically relevant abnormality in the coagulation tests,

          -  Any clinically relevant abnormality in the liver function tests,

          -  History of relevant atopy or drug hypersensitivity,

          -  History of alcoholism and/or drug abuse,

          -  Current consumption of more than 14 units of alcohol per week [1 unit of alcohol = 280
             mL beer (3-4°) = 100 mL wine (10-12°) = 30 mL spirits (40°)],

          -  Any significant infection or known inflammatory process on screening or admission to
             each treatment period,

          -  Any acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at
             the time of screening or admission to each treatment period,

          -  Use of medicines within 2 weeks of admission to first period that could affect the
             subject's safety or other study assessments, in the investigator's opinion,

          -  Previously received opicapone,

          -  Involvement in other clinical trials of any type within 90 days prior to screening,

          -  Participation in more than 2 clinical trials within the 12 months prior to screening,

          -  Blood donation or received any blood transfusion or any blood products within the 3
             months prior to screening,

          -  Vegetarian, vegan or had medical dietary restrictions,

          -  Subject not able to communicate reliably with the investigator,

          -  Subjects who were unlikely to co-operate with the requirements of the study,

          -  Subjects who were unwilling or unable to give written informed consent,

        If female:

          -  Pregnant or breast-feeding,

          -  If of childbearing potential, a positive serum pregnancy test,

          -  Volunteer who did not use an accepted effective contraceptive method or used oral
             contraceptives,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2014</study_first_submitted>
  <study_first_submitted_qc>November 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <results_first_submitted>July 22, 2015</results_first_submitted>
  <results_first_submitted_qc>July 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2015</results_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opicapone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BIA 9-1067 Non-micronized - Micronized</title>
          <description>Each subject was orally administered with 50 mg OPC non-micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC micronized
BIA 9-1067 non-micronized
BIA 9-1067 micronized</description>
        </group>
        <group group_id="P2">
          <title>BIA 9-1067 Micronized - Non-micronized</title>
          <description>Each subject was orally administered 50 mg OPC micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC non-micronized
BIA 9-1067 non-micronized
BIA 9-1067 micronized</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BIA 9-1067 Non-micronized - Micronized</title>
          <description>Each subject was orally administered with 50 mg OPC non-micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC micronized
BIA 9-1067 non-micronized
BIA 9-1067 micronized</description>
        </group>
        <group group_id="B2">
          <title>BIA 9-1067 Micronized - Non-micronized</title>
          <description>Each subject was orally administered 50 mg OPC micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC non-micronized
BIA 9-1067 non-micronized
BIA 9-1067 micronized</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Observed Plasma Concentration</title>
        <description>Maximum observed plasma concentration of BIA 9-1067</description>
        <time_frame>before OPC dosing, and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-OPC dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 Non-micronized</title>
            <description>BIA 9-1067 non-micronized.</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 Micronized</title>
            <description>BIA 9-1067 micronized.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Plasma Concentration</title>
          <description>Maximum observed plasma concentration of BIA 9-1067</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327.8" spread="129.6"/>
                    <measurement group_id="O2" value="750.1" spread="184.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t - Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration</title>
        <description>AUC0-t - Area under the plasma concentration-time curve from time 0 to the time of last quantifiable concentration of BIA 9-1067</description>
        <time_frame>before OPC dosing, and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-OPC dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 Non-micronized</title>
            <description>BIA 9-1067 non-micronized.</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 Micronized</title>
            <description>BIA 9-1067 micronized.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration</title>
          <description>AUC0-t - Area under the plasma concentration-time curve from time 0 to the time of last quantifiable concentration of BIA 9-1067</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1152.8" spread="537.5"/>
                    <measurement group_id="O2" value="2296.5" spread="778.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax - Time of Occurrence of Cmax of BIA 9-1067</title>
        <description>tmax - time of occurrence of maximum observed plasma concentration of BIA 9-1067</description>
        <time_frame>before OPC dosing, and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-OPC dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 Non-micronized</title>
            <description>BIA 9-1067 non-micronized.</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 Micronized</title>
            <description>BIA 9-1067 micronized.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax - Time of Occurrence of Cmax of BIA 9-1067</title>
          <description>tmax - time of occurrence of maximum observed plasma concentration of BIA 9-1067</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf - Area Under the Plasma Concentration-time Curve From Time 0 to the Infinity</title>
        <description>AUC0-inf - Area under the plasma concentration-time curve from time 0 to the infinity.</description>
        <time_frame>before OPC dosing, and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-OPC dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 Non-micronized</title>
            <description>BIA 9-1067 non-micronized.</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 Micronized</title>
            <description>BIA 9-1067 micronized.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - Area Under the Plasma Concentration-time Curve From Time 0 to the Infinity</title>
          <description>AUC0-inf - Area under the plasma concentration-time curve from time 0 to the infinity.</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1327.0" spread="562.0"/>
                    <measurement group_id="O2" value="2324.1" spread="781.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BIA 9-1067 Non-micronized</title>
          <description>BIA 9-1067 non-micronized.</description>
        </group>
        <group group_id="E2">
          <title>BIA 9-1067 Micronized</title>
          <description>BIA 9-1067 micronized.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stiff neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

